Merck KGaA links with AI firm to iron out side-effects during R&DGermany’s Merck KGaA has begun a licensing agreement with Canadian pharma R&D company Cyclica using artificial intelligence (AI) Share XMerck KGaA links with AI firm to iron out side-effects during R&Dhttps://pharmaphorum.com/news/merck-kgaa-links-with-ai-firm-to-iron-out-side-effects-during-rd/
P&G completes acquisition of Merck KGaA’s OTC divisionProcter & Gamble (P&G) has completed its acquisition of Merck KGaA’s Consumer Health business, in a move it Share XP&G completes acquisition of Merck KGaA’s OTC divisionhttps://pharmaphorum.com/news/pg-completes-acquisition-merck-kgaas-otc-division/
Merck KGaA’s bold new approach to cancer immunotherapyGermany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer Share XMerck KGaA’s bold new approach to cancer immunotherapyhttps://pharmaphorum.com/views-analysis-oncology/merck-kgaas-bold-new-approach-to-cancer-immunotherapy/
First line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayCompetition in first line kidney cancer is heating up after Germany’s Merck KGaA and Pfizer briefed the ESMO Share XFirst line kidney cancer could get crowded as Merck KGaA/Pfizer join the frayhttps://pharmaphorum.com/news/first-line-kidney-cancer-inlyta-bavencio/
Merck KGaA’s BTK drug reduces lesions in relapsing MS patientsGermany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) Share XMerck KGaA’s BTK drug reduces lesions in relapsing MS patientshttps://pharmaphorum.com/news/merck-kgaas-btk-drug-reduces-lesions-in-relapsing-ms-patients/
Pfizer/Merck KGaA eye fast review for kidney cancer comboA combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage Share XPfizer/Merck KGaA eye fast review for kidney cancer combohttps://pharmaphorum.com/news/pfizer-merck-kgaa-eye-fast-review-bavencio/
Curious2018: A thirst for innovationAll too often pharma companies are accused of putting shareholders before their patients and society as a whole. Share XCurious2018: A thirst for innovationhttps://pharmaphorum.com/views-and-analysis/curious2018-innovation-thirst/
J&J tops the pharma market cap charts – but for how long?Data and analytics firm GlobalData has tracked the market cap and performance of the top 25 pharma companies Share XJ&J tops the pharma market cap charts – but for how long?https://pharmaphorum.com/views-and-analysis/jj-tops-pharma-market-cap-charts-long/
P&G buys Merck KGaA’s consumer health unit for $4.2bnMerck KGaA is to sell its consumer health business to Procter and Gamble for $4.2 billion, continuing the Share XP&G buys Merck KGaA’s consumer health unit for $4.2bnhttps://pharmaphorum.com/news/pg-buys-merck-kgaas-consumer-health-unit-4-2bn/
